Last reviewed · How we verify
esomeprazole (PPI)
Esomeprazole irreversibly inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.
Esomeprazole irreversibly inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | esomeprazole (PPI) |
|---|---|
| Sponsor | Thomas Jefferson University |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Esomeprazole is the active S-enantiomer of omeprazole that binds to and inactivates the H+/K+-ATPase enzyme (proton pump) on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing intragastric acidity. It is used to treat acid-related disorders by maintaining elevated gastric pH.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prevention of NSAID-induced ulcers
- Helicobacter pylori eradication (as part of combination therapy)
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Constipation
- Flatulence
Key clinical trials
- Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing (PHASE4)
- PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers (PHASE4)
- A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks (NA)
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial (NA)
- Study Comparing Fexuprazan and Esomeprazole in Patients With Gastroesophageal Reflux Disease (PHASE3)
- Heartburn, Gastroesophageal Reflux Disease (PHASE4)
- Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease (NA)
- A Study of Food Effect and Esomeprazole on LY4064809 in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- esomeprazole (PPI) CI brief — competitive landscape report
- esomeprazole (PPI) updates RSS · CI watch RSS
- Thomas Jefferson University portfolio CI